Remove 2019 Remove Diabetes Remove Immunization
article thumbnail

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy for diabetes. . The aim is to replace the pancreatic tissue that is damaged by the autoimmune reaction that underlies type 1 diabetes.

article thumbnail

Vertex buys diabetes cell therapy rival ViaCyte for $320m

pharmaphorum

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The post Vertex buys diabetes cell therapy rival ViaCyte for $320m appeared first on.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines

Express Pharma

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104
article thumbnail

Sanofi begins three-year immunology R&D tie-up with Stanford

pharmaphorum

This latest partnership is in line with the French company’s new focus on immunology after moving away from the cardiovascular disease and diabetes market after CEO Paul Hudson took over in 2019.

article thumbnail

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

article thumbnail

Alzheimer’s Research UK starts AI-based drug hunt with Exscientia

pharmaphorum

In 2019, Novartis also bought into the category via a $310 million takeover of IFM Therapeutics, which is developing NLRP3 drugs for atherosclerosis and non-alcoholic steatohepatitis (NASH), while UK startup NodThera raised $55 million last year for its own NLRP3 programme, eyeing NASH and diabetes.

Diabetes 119
article thumbnail

Edoxaban tosylate by Daiichi Sankyo for Atrial Fibrillation: Likelihood of Approval

Pharmaceutical Technology

It is also indicated for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age more than or equal to 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).